 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| mRNA-3927 / Moderna
Enrollment change: Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia (clinicaltrials.gov) - Oct 26, 2023
P1/2, N=58, Recruiting, Sponsor: ModernaTX, Inc.
N=42 --> 58
- mRNA-3927 / Moderna
mRNA-3927 Therapy for Propionic Acidemia: Interim Data from a Phase 1/2 Study (Room 403 AB) - May 3, 2023 - Abstract #ASGCT2023ASGCT_2278;
P1/2
N=42 --> 58 To date, mRNA-3927 has been well-tolerated at the doses administered, with encouraging early signs of dose-dependent pharmacology and potential clinical benefit.
- || mRNA-3927 / Moderna
PK/PD data, Journal: Translational Pharmacokinetic/Pharmacodynamic Model for mRNA-3927, an Investigational Therapeutic for the Treatment of Propionic Acidemia. (Pubmed Central) - Dec 29, 2022
P1/2
PCCA/B mRNA PK in mice, rats, and monkeys was adequately described using allometric scaling of volume and clearance parameters. The interspecies preclinical model was scaled allometrically to humans to predict the dose-response relationship in adult and pediatric patients with PA to guide selection of dose range and regimen for the Phase 1 clinical trial (ClinicalTrials.gov Identifier NCT04159103).
- || mRNA-3927 / Moderna
New P1/2 trial: A Long-Term Extension Study to Evaluate the Safety and Clinical Activity of mRNA-3927 (clinicaltrials.gov) - Nov 22, 2021
P1/2, N=36, Recruiting, Sponsor: ModernaTX, Inc.
- || mRNA-3927 / Moderna
Enrollment open, Trial completion date, Trial primary completion date: Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia (clinicaltrials.gov) - Mar 16, 2021
P1/2, N=36, Recruiting, Sponsor: ModernaTX, Inc.
The interspecies preclinical model was scaled allometrically to humans to predict the dose-response relationship in adult and pediatric patients with PA to guide selection of dose range and regimen for the Phase 1 clinical trial (ClinicalTrials.gov Identifier NCT04159103). Not yet recruiting --> Recruiting | Trial completion date: Jun 2025 --> Jan 2027 | Trial primary completion date: Jun 2023 --> Mar 2025
- || mRNA-3927 / Moderna
New P1/2 trial: Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia (clinicaltrials.gov) - Nov 14, 2019
P1/2, N=46, Not yet recruiting, Sponsor: ModernaTX, Inc.